A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019.

  title={A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019.},
  author={Walter S. Marcantoni and Bertine Sandra Akoumba and Maggy Wassef and Julie Mayrand and Hinatea Lai and St{\'e}phane Richard-Devantoy and Sylvie Beauchamp},
  journal={Journal of affective disorders},
BACKGROUND Sub-anaesthetic administration of ketamine is an emerging practice in patients presenting treatment resistant depression (TRD), however several outstanding questions have yet to be answered. OBJECTIVE To evaluate the effect of intravenous ketamine infusion for patients presenting TRD on depression scores, clinical remission and response rates, and to assess its efficacy over both time and frequency. METHODS Five databases were searched up to January 4th 2019 to include primary… Expand
Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression
Different treatment modalites including pharmacological interventions, manualized-based psychotherapies, electroconvulsive therapy, transcranial magnetic stimulation, and intravenous monotherapy were examined to determine their impact on the prolongation of antidepressant effects following acute ketamine treatment. Expand
Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)
This first pragmatic pilot trial of adjunctive serial ketamine infusions for hospitalised depression suggests that a definitive trial ofadjunctive ketamine is feasible and generally safe and well tolerated. Expand
Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine
Extending the reach of these novel psychiatric treatments in both tertiary and primary care settings creates an emerging role for pharmacists in the collaborative effort to better manage treatment-resistant depression. Expand
Biomarkers of ketamine’s antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology
Evidence in support of treatment response biomarkers to ketamine is reviewed, with a particular focus on genetics, functional magnetic resonance imaging, and neurophysiological studies, i.e. electroencephalography and magnetoencephalographic studies, to lay the groundwork for replication and dissemination. Expand
Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model
It is suggested that ketamine represents a viable candidate for the treatment of poststroke depression but also thatketamine's lasting antidepressant effects might be achieved through modulation of NMDAR/CaMKII-induced synaptic plasticity in key brain regions. Expand
The Promise of Automated Home-Cage Monitoring in Improving Translational Utility of Psychiatric Research in Rodents
It is argued that over-reliance on behavioral tests that are brief and highly sensitive to external factors play a critical role in this failure and proposed that automated home-cage monitoring offers several advantages that will increase the translational utility of preclinical psychiatric research in rodents. Expand
Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
The evidence suggests that ketamine may result in an increase in response and remission compared with placebo at 24 hours compared with midazolam, and the evidence is very uncertain about the evidence about the response efficacy of ketamine. Expand
Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults
In this systematic review and meta-analysis of 3228 patients with treatment-resistant depression in 50 randomized clinical trials, the placebo effect size was large and consistent across treatment modalities. Expand


A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
It is suggested that single administrations ketamine are efficacious in the rapid treatment of unipolar and bipolar depression and the potential efficacy of other glutamatergic agents. Expand
Ketamine and depression: a narrative review
The level of proof of efficacy remains low and more RCTs are needed to explore efficacy and safety issues of ketamine in depression, as there is a lack of data concerning ketamine with repeated administration at higher doses. Expand
Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
The results suggest that this treatment is effective and well tolerated in this population of TRD patients and is the first published study of sub-anesthetic ketamine infusions in a real-world TRD population. Expand
Ketamine administration in depressive disorders: a systematic review and meta-analysis
The present meta-analysis confirms ketamine’s efficacy in depressive disorders in non-ECT studies, as well as in ECT studies, and further studies are warranted to detail efficacy in bipolar disorders and other specific depressed populations. Expand
Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?
The ketamine infusion was effective in reducing the HDRS scores, and the change remained significant from minute 80 to day 3 postinfusion at each time point, but the change was not significant at any time after day 3. Expand
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
Ketamine was associated with a rapid antidepressant effect in TRD that was predictive of a sustained effect and future controlled studies will be required to identify strategies to maintain an antidepressant response among patients who benefit from a course of ketamine. Expand
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
These pilot findings suggest feasibility of repeated-dose IV ketamine for the acute treatment of TRD and change from baseline in the Montgomery-Asberg Depression Rating Scale score. Expand
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression. Expand
Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)
The results suggest that there is a range of effective, subanesthetic doses of IV ketamine in TRD, including standard dose and high dose of intravenous ketamine were superior to active placebo, and post hoc pairwise comparisons controlling for multiple comparisons suggested this. Expand
Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
A 0.5 mg/kg dose of ketamine infusion was not harmful, but slightly beneficial, for the cognitive function of patients with TRD, and additional studies are necessary to elucidate the effects of repeated ketamines infusion on cognitive function. Expand